Company Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
The company’s product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases.
It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin’s lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases.
The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.
Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 194 |
| CEO | Steven Harr |
Contact Details
Address: 188 East Blaine Street, Suite 400 Seattle, Washington 98102 United States | |
| Phone | 206 701 7914 |
| Website | sana.com |
Stock Details
| Ticker Symbol | SANA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $25.00 |
| CIK Code | 0001770121 |
| CUSIP Number | 799566104 |
| ISIN Number | US7995661045 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven D. Harr M.D. | President, Chief Executive Officer and Director |
| Susan Wyrick | Acting Chief Financial Officer, Treasurer, Principal Accounting Officer and Senior Vice President of Finance and Accounting |
| Snehal Patel | Senior Vice President and Chief Technical Officer |
| Dr. Dhavalkumar D. Patel M.D., Ph.D. | Executive Vice President and Chief Scientific Officer |
| Bernard J. Cassidy J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Sonja Schrepfer M.D., Ph.D. | Senior Vice President and Head of Hypoimmune Platform |
| Dr. Gary Meininger M.D. | Chief Medical Officer |
| Dr. Yuko Soneoka J.D., Ph.D. | Head of Intellectual Property |
| John Gerecitano M.D., Ph.D. | Head of Oncology Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | SCHEDULE 13G/A | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2025 | EFFECT | Notice of Effectiveness |
| Mar 17, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 17, 2025 | 10-K | Annual Report |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 14, 2025 | POSASR | Filing |
| Feb 18, 2025 | 144 | Filing |